By Professor Gail Matthews

Journal articles

Hosseini-Hooshyar S; Alavi M; Martinello M; Valerio H; Tillakeratne S; Matthews GV; Dore GJ, 2022, 'Evaluation of the hepatitis C cascade of care among people living with HIV in New South Wales, Australia: A data linkage study', Journal of Viral Hepatitis, 29, pp. 271 - 279, http://dx.doi.org/10.1111/jvh.13658

Krishnan A; Ellenberger KA; Phetsouphanh C; Kelleher AP; Matthews GV; Darley DR; Holloway CJ, 2022, 'Myocardial fibrosis occurs in non-hospitalised patients with chronic symptoms after COVID-19', Ijc Heart and Vasculature, 39, http://dx.doi.org/10.1016/j.ijcha.2022.100964

Yee J; Carson JM; Hajarizadeh B; Hanson J; O’Beirne J; Iser D; Read P; Balcomb A; Doyle JS; Davies J; Martinello M; Marks P; Dore GJ; Matthews GV; Marks P; Byrne M; Post J; Batey R; Smart J; Dawson O; Hill S; Douglas M; Montebello M; Collie P; Hallinan R; Snelgar G; Baker D; Galhenage S; Soo TM; Bopage R; Faros J; Cooper L; Nelson R; Shaw D; Davies J; Wilson M; Pratt W; Hinton S; Wade A; Van Gessel H; Davidson L; Dibdin M; Lucas M; Ahmad R; Smith D; Tan K; Roder C; Harney B; Holdaway S; Walsh J; Fox P; Mousavi R; Lam W; Dahal RP; Habel P; Gilliver R; Silins E; Ackerman J; Deacon R; Hall E; Everson A; Milner M; Ferguson C; Tate-Baker J; Bradshaw J; Duncan G; Baluran G; Watson B; Hey C; Hickey R; Orme C; Miczkova S, 2022, 'High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study', Hepatology Communications, 6, pp. 496 - 512, http://dx.doi.org/10.1002/hep4.1826

Phetsouphanh C; Darley DR; Wilson DB; Howe A; Munier CML; Patel SK; Juno JA; Burrell LM; Kent SJ; Dore GJ; Kelleher AD; Matthews GV, 2022, 'Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection', Nature Immunology, 23, pp. 210 - 216, http://dx.doi.org/10.1038/s41590-021-01113-x

Krishnan A; Ellenberger K; Chansavath P; Kelleher A; Matthews G; Darley D; Holloway C, 2022, 'Myocardial Fibrosis Occurs in Non-Hospitalised Patients With Chronic Symptoms After COVID-19', Heart, Lung and Circulation, 31, pp. S169 - S170, http://dx.doi.org/10.1016/j.hlc.2022.06.267

Fulford TS; Van H; Gherardin NA; Zheng S; Ciula M; Drummer HE; Redmond S; Tan HX; Boo I; Center RJ; Li F; Grimley SL; Wines BD; Nguyen THO; Mordant FL; Ellenberg P; Rowntree LC; Kedzierski L; Cheng AC; Doolan DL; Matthews G; Bond K; Hogarth PM; McQuilten Z; Subbarao K; Kedzierska K; Juno JA; Wheatley AK; Kent SJ; Williamson DA; Purcell DFJ; Anderson DA; Godfrey DI, 2021, 'A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2', Ebiomedicine, 74, http://dx.doi.org/10.1016/j.ebiom.2021.103729

Valerio H; Alavi M; Law M; McManus H; Tillakeratne S; Bajis S; Martinello M; Matthews GV; Amin J; Janjua NZ; Krajden M; George J; Degenhardt L; Grebely J; Dore GJ, 2021, 'Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study', Clinical Infectious Diseases, 73, pp. 2037 - 2044, http://dx.doi.org/10.1093/cid/ciab526

Feld JJ; Matthews GV, 2021, 'Don't Wait: The Benefits of Early Diagnosis in Perinatal Hepatitis C Virus Transmission', Clinical Infectious Diseases, 73, pp. E3347 - E3348, http://dx.doi.org/10.1093/cid/ciaa942

Acheson LS; Siefried KJ; Clifford B; Murray E; Steele M; Clague L; Malone V; Roberts DM; Ferguson LJ; Matthews GV; Ezard N, 2021, 'One-third of people who inject drugs are at risk of incomplete treatment for Staphylococcus aureus bacteraemia: a retrospective medical record review', International Journal of Infectious Diseases, 112, pp. 63 - 65, http://dx.doi.org/10.1016/j.ijid.2021.09.012

Matthews G, 2021, 'Microelimination of Hepatitis C Among People With Human Immunodeficiency Virus Coinfection: Declining Incidence and Prevalence Accompanying a Multicenter Treatment Scale-up Trial', Clinical Infectious Diseases, http://dx.doi.org/10.1093/cid/ciaa1500

Stafford F; Dore GJ; Clackett S; Martinello M; Matthews GV; Grebely J; Balcomb AC; Hajarizadeh B, 2021, 'Prescribing of direct-acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program', Medical Journal of Australia, 215, pp. 332 - 333, http://dx.doi.org/10.5694/mja2.51204

Carson JM; Hajarizadeh B; Hanson J; O'Beirne J; Iser D; Read P; Balcomb A; Davies J; Doyle JS; Yee J; Martinello M; Marks P; Dore GJ; Matthews GV, 2021, 'Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort', International Journal of Drug Policy, 96, http://dx.doi.org/10.1016/j.drugpo.2021.103422

Darley DR; Dore GJ; Byrne AL; Plit ML; Brew BJ; Kelleher A; Matthews GV, 2021, 'Limited recovery from post-acute sequelae of sars-cov-2 at 8 months in a prospective cohort', Erj Open Research, 7, http://dx.doi.org/10.1183/23120541.00384-2021

Doyle JS; Van Santen DK; Iser D; Sasadeusz J; O'Reilly M; Harney B; Traeger MW; Roney J; Cutts JC; Bowring AL; Winter R; Medland N; Fairley CK; Moore R; Tee BK; Asselin J; El-Hayek C; Hoy JF; Matthews GV; Prins M; Stoové MA; Hellard ME, 2021, 'Microelimination of Hepatitis C among People with Human Immunodeficiency Virus Coinfection: Declining Incidence and Prevalence Accompanying a Multicenter Treatment Scale-up Trial', Clinical Infectious Diseases, 73, pp. E2164 - E2172, http://dx.doi.org/10.1093/cid/ciaa1500

Matthews GV; Bhagani S; Van der Valk M; Rockstroh J; Feld JJ; Rauch A; Thurnheer C; Bruneau J; Kim A; Hellard M; Shaw D; Gane E; Nelson M; Ingiliz P; Applegate TL; Grebely J; Marks P; Martinello M; Petoumenos K; Dore GJ; Marks P; Feld J; Amjad S; Tu E; Tamaddoni M; Thurnheer MC; Gilleece Y; Fraser C; Moriggia A; Lutz T; Moon J; Read P; Ustianowski A; Cordes C; Sasadeusz J; Hull M; Braun D, 2021, 'Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection', Journal of Hepatology, 75, pp. 829 - 839, http://dx.doi.org/10.1016/j.jhep.2021.04.056

Bastard P; Gervais A; Voyer TL; Rosain J; Philippot Q; Manry J; Michailidis E; Hoffmann HH; Eto S; Garcia-Prat M; Bizien L; Parra-Martínez A; Yang R; Haljasmägi L; Migaud M; Särekannu K; Maslovskaja J; De Prost N; Tandjaoui-Lambiotte Y; Luyt CE; Amador-Borrero B; Gaudet A; Poissy J; Morel P; Richard P; Cognasse F; Troya J; Trouillet-Assant S; Belot A; Saker K; Garçon P; Rivière JG; Lagier JC; Gentile S; Rosen LB; Shaw E; Morio T; Tanaka J; Dalmau D; Tharaux PL; Sene D; Stepanian A; Megarbane B; Triantafyllia V; Fekkar A; Heath JR; Franco JL; Anaya JM; Solé-Violán J; Imberti L; Biondi A; Bonfanti P; Castagnoli R; Delmonte OM; Zhang Y; Snow AL; Holland SM; Biggs CM; Moncada-Vélez M; Arias AA; Lorenzo L; Boucherit S; Coulibaly B; Anglicheau D; Planas AM; Haerynck F; Duvlis S; Nussbaum RL; Ozcelik T; Keles S; Bousfiha AA; El Bakkouri J; Ramirez-Santana C; Paul S; Pan-Hammarström Q; Hammarström L; Dupont A; Kurolap A; Metz CN; Aiuti A; Casari G; Lampasona V; Ciceri F; Barreiros LA; Dominguez-Garrido E; Vidigal M; Zatz M; Van De Beek D; Sahanic S; Tancevski I; Stepanovskyy Y; Boyarchuk O; Nukui Y; Tsumura M; Vidaur L; Tangye SG; Burrel S; Duffy D; Quintana-Murci L; Klocperk A, 2021, 'Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths', Science Immunology, 6, http://dx.doi.org/10.1126/sciimmunol.abl4340

Asano T; Boisson B; Onodi F; Matuozzo D; Moncada-Velez M; Renkilaraj MRLM; Zhang P; Meertens L; Bolze A; Materna M; Korniotis S; Gervais A; Talouarn E; Bigio B; Seeleuthner Y; Bilguvar K; Zhang Y; Neehus AL; Ogishi M; Pelham SJ; Le Voyer T; Rosain J; Philippot Q; Soler-Palacín P; Colobran R; Martin-Nalda A; Rivière JG; Tandjaoui-Lambiotte Y; Chaïbi K; Shahrooei M; Darazam IA; Olyaei NA; Mansouri D; Hatipoğlu N; Palabiyik F; Novelli G; Novelli A; Casari G; Aiuti A; Carrera P; Bondesan S; Barzaghi F; Rovere-Querini P; Tresoldi C; Franco JL; Rojas J; Reyes LF; Bustos IG; Arias AA; Morelle G; Kyheng C; Troya J; Planas-Serra L; Schlüter A; Gut M; Pujol A; Allende LM; Rodriguez-Gallego C; Flores C; Cabrera-Marante O; Pleguezuelo DE; de Diego RP; Keles S; Aytekin G; Akcan OM; Bryceson YT; Bergman P; Brodin P; Smole D; Smith CIE; Norlin AC; Campbell TM; Covill LE; Hammarström L; Pan-Hammarström Q; Abolhassani H; Mane S; Marr N; Ata M; Al Ali F; Khan T; Spaan AN; Dalgard CL; Bonfanti P; Biondi A; Tubiana S; Burdet C; Nussbaum R; Kahn-Kirby A; Snow AL; Bustamante J; Puel A; Boisson-Dupuis S; Zhang SY; Béziat V; Lifton RP; Bastard P; Notarangelo LD; Abel L; Su HC, 2021, 'X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19', Science Immunology, 6, http://dx.doi.org/10.1126/sciimmunol.abl4348

Tea F; Stella AO; Aggarwal A; Darley DR; Pilli D; Vitale D; Merheb V; Lee FXZ; Cunningham P; Walker GJ; Fichter C; Brown DA; Rawlinson WD; Isaacs SR; Mathivanan V; Hoffmann M; Pöhlman S; Mazigi O; Christ D; Rockett RJ; Sintchenko V; Hoad VC; Irving DO; Dore GJ; Gosbell IB; Kelleher AD; Matthews GV; Brilot F; Turville SG, 2021, 'SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants', PLoS Medicine, 18, http://dx.doi.org/10.1371/journal.pmed.1003656

Liu B; Jayasundara D; Pye V; Dobbins T; Dore GJ; Matthews G; Kaldor J; Spokes P, 2021, 'Whole of population-based cohort study of recovery time from COVID-19 in New South Wales Australia', Lancet Regional Health Western Pacific, 12, http://dx.doi.org/10.1016/j.lanwpc.2021.100193

Ohata PJ; Su Lwin HM; Han WM; Khwairakpam G; Tangkijvanich P; Matthews GV; Avihingsanon A, 2021, 'Elimination of hepatitis C among HIV-positive population in Asia: Old and new challenges', Future Virology, 16, pp. 407 - 417, http://dx.doi.org/10.2217/fvl-2021-0015

Marriott D; Beresford R; Mirdad F; Stark D; Glanville A; Chapman S; Harkness J; Dore GJ; Andresen D; Matthews GV, 2021, 'Concomitant Marked Decline in Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Other Respiratory Viruses among Symptomatic Patients Following Public Health Interventions in Australia: Data from St Vincent's Hospital and Associated Screening Clinics, Sydney, NSW', Clinical Infectious Diseases, 72, pp. E649 - E651, http://dx.doi.org/10.1093/cid/ciaa1256

Cunningham EB; Hajarizadeh B; Amin J; Hellard M; Bruneau J; Feld JJ; Cooper C; Powis J; Litwin AH; Marks P; Dalgard O; Conway B; Moriggia A; Stedman C; Read P; Bruggmann P; Lacombe K; Dunlop A; Applegate TL; Matthews GV; Fraser C; Dore GJ; Grebely J, 2021, 'Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection among People Who Inject Drugs', Clinical Infectious Diseases, 72, pp. 1392 - 1400, http://dx.doi.org/10.1093/cid/ciaa253

Darley D; Matthews G; Dore G; Wilhelm K; Plit M; Stone E; Byrne A; Tonga K; Andresen D; Kelleher A; Cysique L; Cunningham P; Brew B, 2021, 'Persistent symptoms up to four months after community and hospital- managed SARS- CoV- 2 infection', Medical Journal of Australia, http://dx.doi.org/10.5694/mja2.50963

Archer O; Perram J; Nadel J; Emmanuel S; Matthews G; Beresford R; Holloway CJ, 2021, 'Patients Living with HIV and Coronary Disease: Are we Using Appropriate Anti platelets as Part of Dual Antiplatelet Therapy?', Cardiology & Vascular Research, 5, http://dx.doi.org/10.33425/2639-8486.1094

Valerio H; Alavi M; Law M; Tillakeratne S; Amin J; Janjua NZ; Krajden M; George J; Matthews GV; Hajarizadeh B; Degenhardt L; Grebely J; Dore GJ, 2021, 'High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia', Journal of Hepatology, 74, pp. 293 - 302, http://dx.doi.org/10.1016/j.jhep.2020.08.038

Jin F; Dore GJ; Matthews G; Luhmann N; Macdonald V; Bajis S; Baggaley R; Mathers B; Verster A; Grulich AE, 2021, 'Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis', Lancet Gastroenterology and Hepatology, 6, pp. 39 - 56, http://dx.doi.org/10.1016/S2468-1253(20)30303-4

Bajis S; Applegate TL; Grebely J; Matthews GV; Dore GJ, 2020, 'Novel hepatitic C virus (HCV) diagnosis and treatment delivery systems: Facilitating HCV elimination by thinking outside the clinic', Journal of Infectious Diseases, 222, pp. S758 - S772, http://dx.doi.org/10.1093/infdis/jiaa366

Vogel JP; Tendal B; Giles M; Whitehead C; Burton W; Chakraborty S; Cheyne S; Downton T; Fraile Navarro D; Gleeson G; Gordon A; Hunt J; Kitschke J; McDonald S; McDonnell N; Middleton P; Millard T; Murano M; Oats J; Tate R; White H; Elliott J; Roach V; Homer CSE; McGowan S; Ballenden N; Barrett TL; Beavis V; Saunders JB; Buchanan T; Buchanan-Grey M; Casey D; Cowie M; Doyle J; Frydenberg M; Gnjidic D; Green S; Greenland R; Griffin K; Groombridge S; Hardy L; Hodak A; Holley A; Jovanovska V; Knight S; Michaels K; Morley P; Morphet J; Nou S; Russo P; Sarson M; Young A; Norris S; Morris-Donovan B; Gurry S; Hudson E; Hurley S; Primmer D; Timms S; Whicker S; Mukherjee S; Agostino J; Booth K; Burr L; Byers L; Cameron P; Cooper M; Cheng A; Fowler P; Glanville A; Leder K; McGloughlin S; McMullan B; McPhee E; Mitchell B; Morgan M; Myles P; O’Donnell C; Parr M; Phillips J; Randall R; Varndell W; Whyte I; William L; Brightwell R; Condon L; Deshpande A; Ehm A; Ferrie M; Muller J; Pullin L; Robinson E; Witt A; Larkins S; Morgan M; Taylor G; Agostino J; Burgess P; Agar M; Peiris D; Pearson S; Matthews G; McCarthy S, 2020, 'Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce', Australian and New Zealand Journal of Obstetrics and Gynaecology, 60, pp. 840 - 851, http://dx.doi.org/10.1111/ajo.13270

Dore GJ; Danta M; Matthews GV, 2020, 'Hepatocellular carcinoma risk with antivirals for chronic hepatitis B: no longer confounding', Lancet Gastroenterology and Hepatology, 5, pp. 1028 - 1029, http://dx.doi.org/10.1016/S2468-1253(20)30270-3

Boesecke C; Boyd A; Rauch A; Lacombe K; Rodger A; Pharris A; Pozniak A; Rijnders B; Smit C; Smith C; Hoornenborg E; Wedemeyer H; Schinkel J; Nerlander L; Duffell E; Noori T; Berenguer J; Peters L; Cotte L; Salazar-Vizcaya L; Puoti M; Parczewski M; Martin N; Ingiliz P; Zandkuijl P; Dressler S; Naggie S; van de Laar T; Reiberger T; Matthews G; Bhagani S; Prins M; Rockstroh JK, 2020, 'Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases Consensus panel (vol 34, pg 1699, 2020)', AIDS, 34, pp. 2161 - 2163, http://dx.doi.org/10.1097/01.aids.0000721220.20643.93

Bastard P; Rosen LB; Zhang Q; Michailidis E; Hoffmann HH; Zhang Y; Dorgham K; Philippot Q; Rosain J; Béziat V; Manry J; Shaw E; Haljasmägi L; Peterson P; Lorenzo L; Bizien L; Trouillet-Assant S; Dobbs K; de Jesus AA; Belot A; Kallaste A; Catherinot E; Tandjaoui-Lambiotte Y; Le Pen J; Kerner G; Bigio B; Seeleuthner Y; Yang R; Bolze A; Spaan AN; Delmonte OM; Abers MS; Aiuti A; Casari G; Lampasona V; Piemonti L; Ciceri F; Bilguvar K; Lifton RP; Vasse M; Smadja DM; Migaud M; Hadjadj J; Terrier B; Duffy D; Quintana-Murci L; van de Beek D; Roussel L; Vinh DC; Tangye SG; Haerynck F; Dalmau D; Martinez-Picado J; Brodin P; Nussenzweig MC; Boisson-Dupuis S; Rodríguez-Gallego C; Vogt G; Mogensen TH; Oler AJ; Gu J; Burbelo PD; Cohen JI; Biondi A; Bettini LR; DÁngio M; Bonfanti P; Rossignol P; Mayaux J; Rieux-Laucat F; Husebye ES; Fusco F; Ursini MV; Imberti L; Sottini A; Paghera S; Quiros-Roldan E; Rossi C; Castagnoli R; Montagna D; Licari A; Marseglia GL; Duval X; Ghosn J; Tsang JS; Goldbach-Mansky R; Kisand K; Lionakis MS; Puel A; Zhang SY; Holland SM; Gorochov G; Jouanguy E; Rice CM; Cobat A; Notarangelo LD; Abel L; Su HC; Casanova JL; Arias AA; Darley D; Matthews G, 2020, 'Autoantibodies against type I IFNs in patients with life-threatening COVID-19', Science, 370, pp. eabd4585, http://dx.doi.org/10.1126/science.abd4585

Zhang Q; Liu Z; Moncada-Velez M; Chen J; Ogishi M; Bigio B; Yang R; Arias AA; Zhou Q; Han JE; Ugurbil AC; Zhang P; Rapaport F; Li J; Spaan AN; Boisson B; Boisson-Dupuis S; Bustamante J; Puel A; Ciancanelli MJ; Zhang SY; Béziat V; Jouanguy E; Abel L; Cobat A; Casanova JL; Bastard P; Korol C; Rosain J; Philippot Q; Chbihi M; Lorenzo L; Bizien L; Neehus AL; Kerner G; Seeleuthner Y; Manry J; Le Voyer T; Le Pen J; Schneider WM; Razooky BS; Hoffmann HH; Michailidis E; Rice CM; Sabli IKD; Hodeib S; Sancho-Shimizu V; Bilguvar K; Ye J; Maniatis T; Bolze A; Zhang Y; Notarangelo LD; Su HC; Onodi F; Korniotis S; Karpf L; Soumelis V; Bonnet-Madin L; Amara A; Dorgham K; Gorochov G; Smith N; Duffy D; Moens L; Meyts I; Meade P; Darley D; Tangye S; Matthews G, 2020, 'Inborn errors of type I IFN immunity in patients with life-threatening COVID-19', Science, 370, pp. eabd4570, http://dx.doi.org/10.1126/science.abd4570

Cunningham EB; Hajarizadeh B; Amin J; Litwin AH; Gane E; Cooper C; Lacombe K; Hellard M; Read P; Powis J; Dalgard O; Bruneau J; Matthews GV; Feld JJ; Dillon JF; Shaw D; Bruggmann P; Conway B; Fraser C; Marks P; Dore GJ; Grebely J, 2020, 'Adherence to once-daily and twice-daily direct-acting antiviral therapy for Hepatitis C infection among people with recent injection drug use or current opioid agonist therapy', Clinical Infectious Diseases, 71, pp. E115 - E124, http://dx.doi.org/10.1093/cid/ciz1089

Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV, 2020, 'Moving towards Hepatitis C microelimination among people living with human immunodeficiency virus in Australia: The CEASE study', Clinical Infectious Diseases, 71, pp. 1502 - 1510, http://dx.doi.org/10.1093/cid/ciz985

Han WM; Colby DJ; Khlaiphuengsin A; Apornpong T; Kerr SJ; Ubolyam S; Kroon E; Phanuphak N; Vasan S; Matthews GV; Avihingsanon A; Ruxrungtham K; Phanuphak P; Tangkijvanich P, 2020, 'Large transmission cluster of acute hepatitis C identified among HIV-positive men who have sex with men in Bangkok, Thailand', Liver International, 40, pp. 2104 - 2109, http://dx.doi.org/10.1111/liv.14578

Audsley J; Avihingsanon A; Littlejohn M; Bowden S; Matthews GV; Fairley CK; Lewin SR; Sasadeusz J, 2020, 'Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?', Journal of Acquired Immune Deficiency Syndromes, 84, pp. 527 - 533, http://dx.doi.org/10.1097/QAI.0000000000002386

Gorstein E; Martinello M; Churkin A; Dasgupta S; Walsh K; Applegate TL; Yardeni D; Etzion O; Uprichard SL; Barash D; Cotler SJ; Matthews GV; Dahari H, 2020, 'Modeling based response guided therapy in subjects with recent hepatitis C infection', Antiviral Research, 180, http://dx.doi.org/10.1016/j.antiviral.2020.104862

Valerio H; Alavi M; Matthews G; Law M; McManus H; Amin J; Janjua N; Krajden M; Tillakeratne S; Gleeson V; George J; Degenhardt L; Grebely J; Dore G, 2020, 'Opportunities to enhance linkage to hepatitis C care among people hospitalised for injection drug use-related complications: a population-based study', JOURNAL OF HEPATOLOGY, 73, pp. S807 - S808, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000786587002392&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Denholm JT; Davis J; Paterson D; Roberts J; Morpeth S; Snelling T; Zentner D; Rees M; O'Sullivan M; Price D; Bowen A; Tong SYC; Anderson S; McQuilton Z; Venkatesh B; Hammond N; Jha V; Burston VJ; McMahon J; Charles P; Commons R; O'Brien D; Mahoney A; Sheffield D; Lim LL; Gardiner B; Schulz T; Torresi J; Chean R; Sasadeusz J; Rogers B; Aboltins C; Singh K; Yong M; Lister D; Visvanathan K; Molton J; Tai A; Chalmers R; Martinello M; Wilson P; Gray T; Coghill S; Foo H; Sud A; Williams J; Lwin N; Post J; Van Haal S; Sullivan R; Matthews G; Kwan BCH; Slack A; Shum O; Cochrane B; Dotel R; Gilbey T; Mina M; Su Y; Trethewy C; Hudson B; Chatterji A; Mostert C; New D; Raby E; Hui S; Robinson O; Hart J; Tan SJ; Arellano A; Chambers J; Davis J; Rafiei N; Smith S; Sehu M; Da Silva J; Griffin P; Henderson A; Chaw K; Choong K; Burke A; Heather C; Senanayake S; Boyd M; Rowe E; Anagnostou M; Trad A; Ratcliff A; Dummer J; Bhally H; Giola M; Grimwade K; Chang CLL; Verrall A; Hogg S; Restropo D; Maze M; Ritchie S; Gedye C; Chang J, 2020, 'The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial', Trials, 21, http://dx.doi.org/10.1186/s13063-020-04576-9

Martinello M; Orkin C; Cooke G; Bhagani S; Gane E; Kulasegaram R; Shaw D; Tu E; Petoumenos K; Marks P; Grebely J; Dore GJ; Nelson M; Matthews GV, 2020, 'Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection', Hepatology, 72, pp. 7 - 18, http://dx.doi.org/10.1002/hep.31003

Bradshaw D; Vasylyeva TI; Davis C; Pybus OG; Thézé J; Thomson EC; Martinello M; Matthews GV; Burholt R; Gilleece Y; Cooke GS; Page EE; Waters L; Nelson M, 2020, 'Transmission of hepatitis C virus in HIV-positive and PrEP-using MSM in England', Journal of Viral Hepatitis, 27, pp. 721 - 730, http://dx.doi.org/10.1111/jvh.13286

Grebely J; Read P; Cunningham EB; Weltman M; Matthews GV; Dunlop A; Montebello M; Martinello M; Gilliver R; Marks P; Applegate TL; Dore GJ, 2020, 'Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial', Health Science Reports, 3, http://dx.doi.org/10.1002/hsr2.151

Iranpour N; Dore GJ; Martinello M; Matthews GV; Grebely J; Hajarizadeh B, 2020, 'Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: A retrospective cohort study', Sexual Health, 17, pp. 223 - 230, http://dx.doi.org/10.1071/SH19101

Artenie AA; Cunningham EB; Dore GJ; Conway B; Dalgard O; Powis J; Bruggmann P; Hellard M; Cooper C; Read P; Feld JJ; Hajarizadeh B; Amin J; Lacombe K; Stedman C; Litwin AH; Marks P; Matthews GV; Quiene S; Erratt A; Bruneau J; Grebely J, 2020, 'Patterns of drug and alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis c virus treatment with directacting antiviral therapies: An international study', Clinical Infectious Diseases, 70, pp. 2369 - 2376, http://dx.doi.org/10.1093/cid/ciz633

Dore GJ; Matthews GV, 2020, 'Universal screening for hepatitis C virus infection should be linked to universal treatment access', Nature Reviews Gastroenterology and Hepatology, 17, pp. 321 - 322, http://dx.doi.org/10.1038/s41575-020-0306-8

Dore GJ; Feld JJ; Thompson A; Martinello M; Muir AJ; Agarwal K; Müllhaupt B; Wedemeyer H; Lacombe K; Matthews GV; Schultz M; Klein M; Hezode C; Mercade GE; Kho D; Petoumenos K; Marks P; Tatsch F; Dos Santos AGP; Gane E, 2020, 'Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial', Journal of Hepatology, 72, pp. 431 - 440, http://dx.doi.org/10.1016/j.jhep.2019.10.010

Boettiger DC; Salazar-Vizcaya L; Dore GJ; Gray RT; Law MG; Callander D; Lea T; Rauch A; Matthews GV, 2020, 'Can Australia Reach the World Health Organization Hepatitis C Elimination Goal by 2025 among Human Immunodeficiency Virus-positive Gay and Bisexual Men?', Clinical Infectious Diseases, 70, pp. 106 - 113, http://dx.doi.org/10.1093/cid/ciz164

Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV, 2020, 'Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV', AIDS, 34, pp. 1347 - 1358, http://dx.doi.org/10.1097/QAD.0000000000002562

Hall S; Burns G; Levy M; Lubel J; Nicoll A; Matthews G; Desmond P; Sievert W; Bowden S; Locarnini S; Holmes J; Visvanathan K; Thompson A, 2020, 'A prospective study of nucleot(s)ide analogue discontinuation in non-cirrhotic HBeAg-negative chronic hepatitis B patients: interim analysis at week 48 demonstrates profound reductions of HBsAg associated with ALT flare', Journal of Hepatology, 73, pp. S69 - S70, http://dx.doi.org/10.1016/s0168-8278(20)30674-7

Sharkawy RE; Bayoumi A; Metwally M; Mangia A; Berg T; Romero-Gomez M; Abate ML; Irving WL; Sheridan D; Dore GJ; Spengler U; Lampertico P; Bugianesi E; Weltman M; Mollison L; Cheng W; Riordan S; Santoro R; Gallego-Durán R; Fischer J; Nattermann J; D’Ambrosio R; McLeod D; Powell E; latchoumanin O; Thabet K; Najim MAM; Douglas MW; Liddle C; Qiao L; George J; Eslam M; White R; Rojas A; Bassendine M; Rosso C; Mezzabotta L; Leung R; Malik B; Matthews G; Grebely J; Fragomeli V; Jonsson JR, 2019, 'A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms', Scientific Reports, 9, http://dx.doi.org/10.1038/s41598-018-35736-2

Back to profile page